Diagnosis

UK may take years to recover from long-tail health impact of the pandemic, says Bupa

Retrieved on: 
Monday, May 16, 2022 - 8:00am

That's according to the new Bupa Wellbeing Index, a landmark survey conducted amongst 8,000 UK adults that has uncovered the state of the nation's health and wellbeing.

Key Points: 
  • That's according to the new Bupa Wellbeing Index, a landmark survey conducted amongst 8,000 UK adults that has uncovered the state of the nation's health and wellbeing.
  • It also showed that physical (29%) and mental (34%) health of UK adults declined during the pandemic, exacerbated by lockdowns and the impact of increased remote working.
  • Sedentary lifestyles have also been linked to mental health conditions including depression, anxiety, and chronic stress.
  • The Bupa Wellbeing Index reveals that fitness levels rank lower than mental health, physical health and wellbeing scores3.

US study shows that EIS and Nevisense significantly improves clinicians' diagnostic accuracy

Retrieved on: 
Monday, May 16, 2022 - 7:12am

The study showed a significant increase in diagnostic accuracy with Nevisense, especially for respondents who reported rarely using dermoscopy.

Key Points: 
  • The study showed a significant increase in diagnostic accuracy with Nevisense, especially for respondents who reported rarely using dermoscopy.
  • "The study results showed that EIS may complement dermoscopy by helping a broader range of providers make improved PSL diagnostic decisions.
  • "The study further demonstrates the positive impact Nevisense has in the diagnostic process for clinicians when evaluating atypical pigmented skin lesions.
  • The study showed that the addition of the Nevisense EIS data significantly increased the accuracy of clinicians.

PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma

Retrieved on: 
Sunday, May 15, 2022 - 6:24pm

PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.

Key Points: 
  • PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
  • AstraZenecas ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.
  • Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
  • The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK.

New Real-World Evidence Shows Improvements in Outcomes and Reduction in Healthcare Costs with Guidance® UTI Precision Diagnostic Test Compared to Standard Urine Culture in Patients with Complicated Urinary Tract Infections

Retrieved on: 
Saturday, May 14, 2022 - 9:30pm

IRVINE, Calif., May 14, 2022 /PRNewswire/ -- Real-world evidence from a Medicare database analysis presented today at the 2022 American Urology Association (AUA) Meeting shows that Guidance UTI testing is associated with reductions in critical adverse outcomes, healthcare resource utilization and costs for complicated urinary tract infections (cUTIs) compared to standard urine culture (SUC). The comparative analysis was designed to examine outcomes of one year of cUTI treatment guided by either Guidance UTI or SUC.

Key Points: 
  • The findings reinforce the real-world benefits of Guidance UTI's increased sensitivity, reduced time to results, and P-AST results to patients, providers, and the healthcare system."
  • UTI-related clinical, healthcare use and costs outcomes were then tracked for one year.
  • Guidance UTI testing was associated with 44% lower total costs and 77% lower clinically-advanced costs* compared to SUC, and cUTIs in the Guidance UTI cohort were likelier to be managed successfully as outpatients.
  • The rate of outpatient emergency visits was 13% lower and inpatient admissions were 67% lower when using Guidance UTI compared to SUC.

Calliditas Therapeutics Launches an Online Patient Platform

Retrieved on: 
Saturday, May 14, 2022 - 1:00pm

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (Calliditas) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
  • Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions.
  • With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.
  • Calliditas common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

Retrieved on: 
Friday, May 13, 2022 - 9:21pm

We are excited about the collaboration with AstraZeneca to investigate the combination of SI-B001 and a leading third-generation EGFR TKI for patients with NSCLC.

Key Points: 
  • We are excited about the collaboration with AstraZeneca to investigate the combination of SI-B001 and a leading third-generation EGFR TKI for patients with NSCLC.
  • SI-B001 can also induce endocytosis of EGFR and HER3, and down-regulate the levels of EGFR and HER3 tumor cells.
  • Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.
  • With multiple in-house proprietary platforms for innovative biopharmaceuticals, Baili has built a robust pipeline to benefit cancer patients around the world.

FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes

Retrieved on: 
Friday, May 13, 2022 - 8:35pm

SILVER SPRING, Md., May 13, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.   

Key Points: 
  • Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.
  • Type 2 diabetes, the most common form of diabetes, is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose (sugar) in the blood.
  • More than 30 million Americans have type 2 diabetes.
  • Despite the availability of many medications to treat diabetes, many patients do not achieve the recommended blood sugar goals.

Worldwide Polyclinics Industry to 2027 - Focus on Large Scale Polyclinic v/s Express Clinics - ResearchAndMarkets.com

Retrieved on: 
Friday, May 13, 2022 - 3:44pm

The "Global Polyclinics Market, By Type (Large Scale Polyclinic v/s Express Clinic), By Services (Diagnostic, Consultation, Treatment), By Therapy Area, By Region, Competition Forecast and Opportunities, 2017-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Polyclinics Market, By Type (Large Scale Polyclinic v/s Express Clinic), By Services (Diagnostic, Consultation, Treatment), By Therapy Area, By Region, Competition Forecast and Opportunities, 2017-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global polyclinics market is expected to grow at a significant rate during the forecast period.
  • Besides, the rising instances of infectious diseases and the increasing geriatric population are expected to propel the growth of the global polyclinics market.
  • Moreover, government authorities are constructing polyclinics instead of the hospital in remote areas situated in difficult terrains, stimulating the growth of the global polyclinics market.

Phase III LINC 3 Study Demonstrates That ISTURISA® (osilodrostat) Improves Physical Features Associated With Hypercortisolism in Patients With Cushing’s Disease

Retrieved on: 
Friday, May 13, 2022 - 2:00pm

Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushings disease.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushings disease.
  • Patients with Cushings disease experience multiple physical manifestations of hypercortisolism that may reduce quality of life.
  • According to the abstract entitled Osilodrostat Therapy Improves Physical Features Associated with Hypercortisolism in Patients with Cushings Disease: Findings from the Phase III LINC 3 Study, 137 adult Cushings disease patients with mUFC >1.5 x the upper limit of normal were enrolled in the 48-week core phase to evaluate the safety and efficacy of ISTURISA in patients with Cushings disease.
  • Changes to physical features caused by Cushings disease can have a significant impact on patient health and well-being.

iMediSync Leads Global Remote Healthcare Market With Its AI-Based Brain Scanning Device iSyncWave

Retrieved on: 
Friday, May 13, 2022 - 2:00pm

Aligned with this, iSyncWave , an innovative AI-based brain-scanning device, gained global media attention during the event.

Key Points: 
  • Aligned with this, iSyncWave , an innovative AI-based brain-scanning device, gained global media attention during the event.
  • iSyncWave is the worlds first integrated wireless EEG measurement and Neurotherapy convergence solution and is a remote-care mental health platform device.
  • The device is a 100 percent dry-type headset equipped with the age/gender matching normative database with 1,300+ healthy brainwaves covering almost all ages.
  • Also, the device is equipped with PBM (Photobiomodulation) LED therapy to suppress brain cells from dying, which provides personalized therapy protocols that target neuro-related diseases.